Cross-disease Meta-analysis of Genome-wide Association Studies for Systemic Sclerosis and Rheumatoid Arthritis Reveals IRF4 as a New Common Susceptibility Locus by López Isac, Elena et al.
 
Running head: IRF4, a new SSc-RA shared locus 
Title: Cross-disease Meta-analysis of Genome-wide Association Studies 
for Systemic Sclerosis and Rheumatoid Arthritis Reveals IRF4 as a New 
















 MD PhD, Emma 
Beltrán
7
 MD, Javier Narváez
8 
MD PhD, Juan J Alegre-Sancho
9 





MD PhD, Alejandro Balsa
12 
MD PhD, Ana M Ortiz
13 
MD 
PhD, Miguel A González-Gay
14 











MD PhD, Armando 
Gabrielli
17 
MD PhD, Torsten Witte
18 
MD PhD, Nicolas Hunzelmann
19 





MD PhD, Annete H van der Helm-van Mil
22 
MD PhD, Jeska de Vries-
Bouwstra
22 
MD PhD, Cesar Magro-Checa
22 
MD, Alexandre E Voskuyl
23 
MD, Madelon C Vonk
24 
MD PhD, Øyvind Molberg
25 











MD PhD, Steve Eyre
29 
MD 
PhD, Bobby PC Koeleman
30 
PhD, Christopher P Denton
31 





 MD PhD, Jane Worthington
29 






1. Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, PTS Granada, Granada, 
Spain. 
2. The University of Texas Health Science Center–Houston, Houston, USA. 
3. Department of Internal Medicine, Valle de Hebrón Hospital, Barcelona, Spain. 
4. Department of Rheumatology, 12 de Octubre University Hospital, Madrid, Spain. 
5. Department of Internal Medicine, Clinic University Hospital, Granada, Spain. 
6. Department of Internal Medicine, Thrombosis and Vasculitis Unit, Complexo Hospitalario 
Universitario de Vigo, Vigo, Spain. 
7. Department of Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain. 
8. Department of Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain. 
9. Department of Rheumatology, Hospital Universitari Doctor Peset, Valencia, Spain. 
10. See supplementary note. 
11. Rheumatology Service, Hospital Clínico San Carlos, Madrid, Spain. 
Brief Report Arthritis & Rheumatology
DOI 10.1002/art.39730
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as an
‘Accepted Article’, doi: 10.1002/art.39730
© 2016 American College of Rheumatology
Received: Dec 11, 2015; Revised: Mar 30, 2016; Accepted: Apr 19, 2016
This article is protected by copyright. All rights reserved.
2 
 
12. Rheumatology Unit, Hospital Universitario La Paz, Instituto de Investigación Sanitaria La Paz. 
IdiPAZ. Madrid, Spain.  
13. Rheumatology Service, Hospital Universitario La Princesa, Instituto de Investigación Sanitaria 
La Princesa, Madrid, Spain. 
14. Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory 
Diseases, DIVAL, University of Cantabria, Santander, Spain.   
15. Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca' Granda Ospedale 
Maggiore Policlinico di Milano, Milan Italy. 
16. Department of Medicine, Università degli Studi di Verona, Verona, Italy. 
17. Clinica Medica, Department of Clinical and Molecular Science, Università Politecnica delle 
Marche and Ospedali Riuniti, Ancona,  Italy. 
18. Department of Clinical Immunology, Hannover Medical School, Hannover, Germany. 
19. Department of Dermatology, University of Cologne, Cologne, Germany.  
20. Department of Internal Medicine, Institute for Clinical Immunology, University of Erlangen-
Nuremberg, Erlangen, Germany. 
21. Clinic of Rheumatology, University of Lübeck, Lübeck , Germany  
22. Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. 
23. Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. 
24. Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, The 
Netherlands. 
25. Rheumatology Unit, Oslo University Hospital Rikshospitalet and Institute of Clinical Medicine, 
University of Oslo, O slo, Norway. 
26. Department of Biochemistry, University of Otago, New Zealand. 
27. Department of Rheumatology, Lund University, Lund, Sweden. 
28. Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska 
Institutet, Stockholm, Sweden. 
29. Centre for Musculoskeletal Research and NIHR Manchester Musculoskeletal Biomedical 
Research Unit, The University of Manchester, Manchester Academic Health Science Centre, 
Manchester, UK. 
30. Section Complex Genetics, Department of Medical Genetics, University Medical Center 
Utrecht, Utrecht, The Netherlands. 
31. Centre for Rheumatology, Royal Free and University College Medical School, London, United 
Kingdom. 
32. Department of Rheumatology & Clinical Immunology, Laboratory of Translational 





Javier Martin MD, PhD 
Page 3 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
3 
 
Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC. Parque Tecnológico Ciencias de la 
Salud. Avenida del Conocimiento s/n 18016-Armilla (Granada), Spain. 
E-mail: martin@ipb.csic.es 
Tel: 34 958181669 
Fax: 34 958181632 
Elena López-Isac 
Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC. Parque Tecnológico Ciencias de la 






This work was supported by the following grants: JM was funded by SAF2012-34435 
from the Spanish Ministry of Economy and Competitiveness, the EU/EFPIA Innovative 
Medicines Initiative Joint Undertaking PRECISESADS (ref: 115565) and BIO-1395 from 
Junta de Andalucía. NO was funded by PI-0590-2010, from Consejería de Salud y 
Bienestar Social, Junta de Andalucía, Spain. ELI was supported by Ministerio de 
Educación, Cultura y Deporte through the program FPU. TRDJR was funded by the VIDI 
laureate from the Dutch Association of Research (NWO) and Dutch Arthritis Foundation 
(National Reumafonds). Study on USA samples were supported by the Institutes of Health 
(NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 
Centers of Research Translation (CORT) grant P50AR054144 (MDM), the NIH-NIAMS 
SSc Family Registry and DNA Repository (N01-AR-0-2251) (MDM), NIH-
Page 4 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
4 
 
KL2RR024149-04 (SA), NIH-NCRR 3UL1RR024148, US NIH NIAID UO1 
1U01AI09090, K23AR061436 (SA), Department of Defense PR1206877 (MDM) and 
NIH/NIAMS-RO1- AR055258 (MDM). 
ACKNOWLEDGMENTS  
We thank Sofia Vargas, Sonia García and Gema Robledo for her excellent technical 
assistance and all the patients and control donors for their essential collaboration. We thank 
National DNA Bank Carlos III (University of Salamanca, Spain) who supplied part of the 
control DNA samples. We also would like to thank the following organizations: The 
EULAR Scleroderma Trials and Research group (EUSTAR), the German Network of 







Page 5 of 38
John Wiley & Sons
Arthritis & Rheumatology




Objectives: Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune 
diseases that share clinical and immunological characteristics. To date, several shared SSc-
RA loci have been identified independently. In this study, we aimed to systematically 
search for new common SSc-RA loci through an inter-disease meta-GWAS strategy. 
Methods: We performed a meta-analysis combining GWAS datasets of SSc and RA using 
a strategy that allowed identification of loci with both same-direction and opposing-
direction allelic effects. The top single-nucleotide polymorphisms (SNPs) were followed-up 
in independent SSc and RA case-control cohorts. This allowed us to increase the sample 
size to a total of 8,830 SSc patients, 16,870 RA patients and 43,393 controls.  
Results: The cross-disease meta-analysis of the GWAS datasets identified several loci with 
nominal association signals (P-value < 5 x 10
-6
), which also showed evidence of 
association in the disease-specific GWAS scan. These loci included several genomic 
regions not previously reported as shared loci, besides risk factors associated with both 
diseases in previous studies. The follow-up of the putatively new SSc-RA loci identified 
IRF4 as a shared risk factor for these two diseases (Pcombined = 3.29 x 10
-12
). In addition, the 
analysis of the biological relevance of the known SSc-RA shared loci pointed to the type I 
interferon and the interleukin 12 signaling pathways as the main common etiopathogenic 
factors. 
Conclusions: Our study has identified a novel shared locus, IRF4, for SSc and RA and 
highlighted the usefulness of cross-disease GWAS meta-analysis in the identification of 
common risk loci.  
KEYWORDS 
Systemic sclerosis, rheumatoid arthritis, genome-wide association study, shared loci. 
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Genome-wide association studies (GWASs) and immune-focused fine-mapping studies 
have revolutionized our understanding of the genetic component of complex autoimmune 
diseases (ADs) by the identification of thousands of susceptibility loci associated with 
autoimmunity (1). The vast majority of these loci are shared risk factors for at least two or 
more ADs, pointing to a common genetic background underlying autoimmune processes. 
This genetic overlap has been suspected some time ago, given the high rate of co-
occurrence of ADs and the well-established familial aggregation reported for these immune 
disorders (1).  
Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are complex ADs which share 
clinical and immunological features. Both diseases are rheumatic connective tissue 
disorders, characterized by an exacerbated inflammatory response, deregulation of innate 
and adaptive immunity, including autoantibody production, and systemic complications. 
Thanks to the establishment of large consortiums and international collaborations, the 
number of confirmed RA susceptibility factors has increased up to a total of 101 loci 
associated with the disease at the genome-wide significance level (2). In regard to SSc, 
GWASs, Immunochip and candidate gene studies have clearly identified various genetic 
regions involved in SSc susceptibility (3). However, the knowledge of the genetic 
predisposition to this disease is relatively limited, in part due to its low prevalence, which 
impairs the recruitment of large cohorts required to reach a high statistical power and to 
effectively detect association signals. Interestingly, a considerable proportion of the SSc 
susceptibility factors also represent RA risk loci (2-3). In addition, although not very 
common, co-familiarity and co-occurrence between these two rheumatic conditions have 
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been observed (4). These observations provide evidence of a genetic overlap for both 
diseases, thus it is expected that additional shared risk factors remain to be discovered. 
One approach that has been developed for the identification of common loci in a cost-
effective manner is to perform a combined-phenotype GWAS, that is, to combine genome-
wide genotype data from two autoimmune diseases. This strategy has been successfully 
applied not only to the study of closely related phenotypes but also to non-related 
phenotypes, showing encouraging results (5). 
Taking into account all these considerations, the purpose of the present study was to 
systematically identify new common risk loci for SSc and RA by applying the combined-
phenotype GWAS strategy, followed by replication testing in independent case-control 
datasets. 
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The stage I of the present study included 6,537 SSc/RA patients and 8,741 healthy 
controls. The SSc GWAS panel comprised four case-control sets from Spain, Germany, 
The Netherlands and US (2,716 cases and 5,666 controls) which were obtained from 
previous studies (5-7). The RA case-control GWA study included two previously published 
RA GWAS cohorts (WTCCC, EIRA) from UK and Sweden (3,821 cases and 3,075 
controls) (8).  
The replication stage was drawn in independent SSc and RA case-control sets of 
European ancestry. The SSc replication cohort included 6,114 cases and 8,744 controls 
from 8 different countries (Spain, Germany, Italy, UK, The Netherlands, Sweden, Norway 
and US). The healthy controls from UK and US partially overlapped with control sets of 
previously published cohorts (WTCCC and NARAC2) (8). The RA replication cohort 
included 9 case-control collections from North America (US, Canada), Spain, The 
Netherlands, UK, Sweden, France and New Zealand, and comprised a total of 13,049 RA 
cases and 25,908 healthy controls.  Of these, 9,711 cases and 24,253 healthy controls were 
obtained from several previously published studies (BRASS, NARAC1, CANADA, RACI-
US, RACI-i2b2, CORRONA, Vanderbilt, RACI-UK, RACI-SE-U, RACI-NL, Dutch 
(AMC, BeSt, LUMC, and DREAM), ReAct, ACR-REF) (2). All SSc and RA patients 
fulfilled previously described classification criteria for SSc and RA respectively (2, 5). All 
individuals enrolled in the present study provided written informed consent and approval 
from the local ethical committees was obtained from all the centers in accordance with the 
tenets of the Declaration of Helsinki. 
Study design 
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In the present study, we performed a two-stage study to systematically identify SSc-RA 
shared risk factors (Figure 1). 
Stage I. We performed GWAS analysis for each disease separately and a combined-
phenotype GWAS analysis. Two different tests were considered for the combined analysis 
(5): 
1)  To detect common signals for SSc and RA with same-direction allelic effects, the 
meta-analysis considering both diseases was performed as usual. Those SNPs that showed a 
P-value < 5 x 10
-6
 in the combined-phenotype analysis and nominal significance in the 
association study for each disease (P-value < 0.05) were selected for follow-up in the 
replication stage. 
2) To identify common signals with opposite-direction allelic effects, we flipped the 
direction of association (1/OR) in the RA dataset for the combined-disease meta-analysis. 
To select SNPs for replication, the same selection criteria stated above were followed.  
For both sorts of meta-analyses, we only considered for follow-up those SNPs that had 
not been previously reported as genetic risk factors for SSc and RA, or those that had been 
reported for one disease but not reported for the other.  
Stage II.  The selected SNPs were followed-up in independent replication cohorts. 
Subsequently, we performed a meta-analysis of the initial GWAS screening and replication 
stages. The SNP signals that reached (1) genome-wide significance level (P-value < 5 x 10
-
8
) in the combined-phenotype meta-analysis (GWAS + Replication stage), and (2) showed , 
for each disease separately, nominally significant associations (P-value < 0.05) in the 
replication step as well as PGWAS+Repl < 5 x 10
-3 
were considered shared risk factors for the 
two analyzed diseases.  
Quality control and genotype imputation of GWAS data 
Page 11 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
11 
 
We applied stringent quality control (QC) criteria in all the GWAS datasets. Cutoff 
values for sample call rate and SNP call rate were set up at 95%. Markers with allele 
distributions deviating from Hardy-Weinberg equilibrium (HWE) (P-value < 0.001) in 
controls from any of the populations analyzed separately were excluded. Markers with 
minor allele frequencies (MAF) lower than 1% were filtered out. After QC, we performed 
whole-genome genotype imputation with IMPUTE2 software (9) using the CEU and TSI 
populations of the HapMap Phase 3 project as reference panels (http://www.hapmap.org). 
Imputed SNP quality was assessed by establishing a probability threshold for merging 
genotypes at 0.9. Subsequently, stringent QC was applied to the imputed data using the 
same criteria stated above. After that, genome-wide genotyping data were available for a 
total of 219,756 SNPs. The first 5 principal components (PC) were estimated and 
individuals deviating more than six standard deviations (SDs) from the cluster centroids 
were considered outliers. In addition, duplicate pairs or highly related individuals among 
datasets were also removed on the basis of pairwise comparisons by using the Genome 
function in PLINK v1.7 (http://pngu.mgh.harvard.edu/purcell/plink/) (Pi-HAT threshold of 
0.5).  
Follow-up genotyping 
The genotyping of the replication cohorts was performed with either (1) TaqMan SNP 
genotyping technology in a LightCycler® 480 Real-Time PCR System (Roche Applied 
Science, Mannheim, Germany), or (2) the GWAS  and Immunochip platforms.  
For the SSc study, all cases were genotyped by TaqMan genotyping system using 
TaqMan 5’ allele discrimination predesigned assays from Applied Biosystems. Genotyping 
call rate was > 95% for the three SNPs. The control samples were also genotyped by this 
technology, with the exception of the UK and USA cohorts. For these two control cohorts, 
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genotyping data were obtained from previously published genome-wide genotyping 
datasets (WTCCC and NARAC2) (8).  
RA cases from Spain and New Zealand and Spanish controls were genotyped by 
TaqMan technology. Genotype data for New Zealand  healthy controls partially overlapped 
with those from a previous GWAS report (10). For the remaining RA case-control sets, 
genotype frequencies and association data were obtained from a previously published study 
(2). Genotype methods of these studies were described in detail in Okada et al. (2). For 
those cohorts that were genotyped with the Illumina Immunochip platform, only data for 
IRF4 rs9328192 were available.       
Data analysis 
 All data were analyzed using PLINK. To test for association, we performed logistic 
regression analysis in each of the SSc and RA GWAS cohorts separately.  The first 5 PC 
were included as covariates to control for any potential population stratification effects. The 
replication cohorts were also analyzed by logistic regression analysis. The meta-analyses 
were performed with inverse-variance method based on population specific logistic 
regression results. Heterogeneity of the ORs across studies was assessed using Cochran’s Q 
test. HWE was tested for all the validation cohorts genotyped by TaqMan technology 
(HWE P-values < 0.01 were considered to show significant deviation from equilibrium). 
None of the included control cohorts showed significant deviation from HWE, with the 
exception of HNF1A rs10774577. The cohorts that failed HWE were excluded for the 
analysis of this specific SNP. The statistical power of the combined analysis is shown in 
Supp. Table 1. 
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In the stage I of this study we conducted a cross-disease meta-analysis in order to 
systematically identify new putatively shared loci between SSc and RA. The overall 
workflow of the study is illustrated in Figure 1. 
The meta-analysis combining both datasets identified various SNPs from seven distinct 
genomic regions showing a P-value < 5 x 10
-6
, as well as a nominal signal of association 
(P-value < 0.05) in the disease-specific analyses. The strongest association was found in the 
well accepted SSc and RA associated locus IRF5 (Pcombined = 8.44 x 10
-17
; SSc PGWAS = 
1.14 x 10
-16
; RA PGWAS = 7.86 x 10
-4
). Three additional SSc-RA known loci, namely 
PTPN22, ATG5 and BLK, were also identified at this stage (Figure 2, Supp. Table 2 and 
Supp. Figure 1). The remaining SNPs were located in three different loci: FBN2 and 
HNF1A that had not been previously reported as genetic risk factors for SSc and RA; and 
IRF4, associated with RA in previous studies (Table 1, Figure 2, and Supp. Figure 2). 
Interestingly, the regional association plots of FBN2, IRF4 and HNF1A loci showed that the 
top SNPs of the combined analysis were also the top SNPs in the analyses for SSc and RA 
separately, or at least were in high linkage disequilibrium with the top signal observed for 
each disease (Supp. Figure 2). These putatively new shared SNPs were selected for follow-
up in additional SSc and RA replication cohorts. For IRF4, three SNPs met our criteria for 
being selected for validation in the replication step. In this case, we selected the SNP with 
the lowest P-value (Supp. Table 2).  
Replication Phase and meta-analysis.  
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According to the established thresholds (see Methods section for more details), we 
identified one new association signal shared between SSc and RA at IRF4 for SNP 
rs9328192 (Pcombined = 3.29 x 10
-12
). Furthermore, this IRF4 SNP almost reached genome-
wide significance in the meta-analysis for each disease separately (SSc PGWAS+Repl = 2.78 x 
10
-7
, OR = 0.90; RA PGWAS+Repl = 1.44 x 10
-6
, OR = 1.08) (Table 1).  
Regarding HNF1A and FBN2 genetic variants, despite the initial suggestive association 
signals found in the first stage, these loci did not show genome-wide significance in our 
combined-phenotype meta-analysis. Nevertheless, HNF1A rs10774577 showed suggestive 
evidence of association in the meta-analysis performed in SSc alone (SSc PRepl = 0.036, OR 
= 0.94; SSc PGWAS+Repl = 1.64 x 10
-4
, OR = 0.91), and a P-value of 1.59 x 10
-6 
in the 
combined-phenotype meta-analysis. Considering that this SNP was not included in those 
cohorts that were genotyped with Immunochip, the present study had a lower statistical 
power for the analysis of this genomic region. Therefore, a slight or modest genetic effect 
of HNF1A rs10774577 cannot be ruled out and further studies will be required to establish 
whether this locus is a shared SSc–RA risk factor.   
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In the present study we have identified a novel non-HLA susceptibility locus shared 
between SSc and RA, namely IRF4, by a combined-phenotype GWAS strategy in large 
case-control cohorts of SSc and RA. This locus, IRF4, was already reported to be involved 
in RA susceptibility, but had not been previously associated with SSc (2). 
The cross-disease meta-analysis performed with the SSc and RA GWAS datasets 
identified various SNPs from seven different loci that met our stringent selection criteria for 
the replication phase (Pcombined < 5 x 10
-6
; SSc PGWAS < 0.05; RA PGWAS < 0.05). Four of 
them were already SSc and RA risk factors (PTPN22, ATG5, IRF5 and BLK), thus 
providing support for the effectiveness of this strategy in the identification of shared risk 
loci (2-3). It is worth mentioning that these loci were detected by the two different tests 
used in the first stage, which were performed in order to detect both same-direction and 
opposite-direction allelic effects. In fact, the new shared IRF4 SNP identified in this study 
showed opposite effects for SSc and RA (protection and risk effects, respectively).  This 
discrepancy might be due to the fact that the actual causal variants for the associations in 
each disease could be different and IRF4 rs9328192 is tagging them. This discordant 
phenomenon is particularly common between ADs (1). However, to completely understand 
these discordant effects, the interaction with other genetic variants contributing to disease 
susceptibility should be considered, besides analyze the precise biological impact of the 
associations.    
The associated IRF4 SNP (rs9328192) showed modest effect sizes for SSc and RA. 
However, we were able to capture this association in our meta-analysis thanks to the large 
cohort used in this study together with the combined-phenotype approach, which allowed 
us to increase the statistical power. This highlights the capability of the combined-
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phenotype approach in the identification of shared variants with low penetrance, whose 
associations might have been missed in disease-specific GWASs due to a lack of power 
(11). 
Interferon regulatory factor 4 (IRF4) belongs to the IRF family of transcription factors 
and plays a pivotal role in the development and function of several autoimmune-associated 
cells (12). Various genetic and functional studies have pointed to IRF4 as a master 
regulator for autoimmunity (12-13). It has been demonstrated that IRF4 is a crucial factor 
for the editing and L-chain rearrangements of the B cell receptor, and the pre-B cell 
expansion, which are processes directly related with the development of autoimmunity 
(14).  In addition, IRF4 is a critical controller of the T helper 17 cells (Th17) differentiation 
and the production of interleukin (IL) 17 and 21(12), which are immune system 
components that play a key role in the pathogenesis of SSc and RA.  
The results of the present study add another interferon regulatory factor to the list of 
IRFs associated with SSc (IRF4, IRF5, IRF7 and IRF8) and RA (IRF4, IRF5 and IRF8) (2-
3), thus providing genetic support for the IFN signature described for SSc and RA patients 
(15). Moreover, our pathway enrichment analysis also identified the type I IFN signaling 
pathway as one of the most relevant common pathways between SSc and RA on the basis 
of their common genetic background (Supp. Methods, Supp. Figure 3, Supp. Table 3). 
Therefore, deregulation of this signaling pathway might be a biological process underlying 
the onset of these two autoimmune rheumatic conditions. 
In summary, through a cross-disease meta-analysis of GWASs for SSc and RA, we were 
able to identify IRF4 as a new shared susceptibility locus for SSc and RA. The present 
study, together with previous reports, reinforces the idea of a common genetic background 
between SSc and RA. The identification of these pleiotropic autoimmunity loci may point 
Page 17 of 38
John Wiley & Sons
Arthritis & Rheumatology
This article is protected by copyright. All rights reserved.
17 
 
to common pathogenic pathways, which ultimately may represent a clinical advantage, thus 
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Table 1.  Association results of the cross-disease meta-GWAS for three selected SNPs. 
        


























Meta   























(5) rs6897611 T 4.79E-07 2.85E-03 1.16 0.641 0.98 0.165 1.04 3.15E-05 1.24 0.684 0.99 0.650* 1.02* 0.018 - 
IRF4 




(12) rs10774577** T 7.53E-07 8.62E-04 0.89 0.036 0.94 1.64E-04 0.91 2.50E-04 1.14 0.290 1.03 0.208* 1.05* 1.59E-06 - 
+
 Odds ratio for the reference allele. 
* P-value and OR from meta-analysis under random effects due to heterogeneity of the ORs among cohorts. 
**The RA and SSc replication cohorts from Spain, and the SSc replication cohorts from Italy and The Netherlands were excluded from the analysis of rs10774577 due to HWE 
issues. 
Chr, chromosome; GWAS, genome-wide association study; OR, odds ratio; RA, rheumatoid arthritis; Repl, replication; SNP, single nucleotide polymorphism; SSc, systemic sclerosis. 
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Figure 1. Overall workflow of the present study. 
Figure 2.  Manhattan plot showing the results of the cross-disease meta-GWAS. The -log10 
of the combined-phenotype meta-analysis P-values are plotted against their physical 
chromosomal position. The plot displays the -log10 P-values from the same-direction meta-
analysis of SSc and RA. The signals from the opposite-direction meta-analysis that reached the 
selection criteria are also plotted (red points). The red line represents the threshold at 5 x 10
-6
. 
Those loci with SNPs that reached the selection criteria for the replication phase are plotted (loci 
selected for follow-up are highlighted in pink). 
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SUPPLEMENTARY MATERIAL 
SUPPLEMENTARY METHODS  
Biological connection across SSc-RA shared loci 
In order to gain insight into the common etiopathogenic factors that underlie SSc and 
RA, we performed functional protein association analyses considering the shared risk 
factors described to date between SSc and RA. For this purpose, we only included firmly 
associated loci for both diseases, which were selected on the basis of the following criteria: 
(1) loci associated at the genome-wide significance level (P-value 5 x 10
-8
), (2) those that 
reached second tier level associations (p-value < 5x10
-5
), or (3) that have been  replicated in 
independent studies. In total, 14 well-established SSc-RA loci were included (Supp. Figure 
3).   
Protein-protein interaction (PPI) analysis. PPIs among the 14 SSc-RA loci were 
interrogated using STRING V.10 that provides a critical integration of PPIs, including 
direct (physical) as well as indirect (functional) associations.(1) A confidence score of 
0,400 was applied.  
Molecular pathway enrichment analysis.  We conducted molecular pathway enrichment 
analyses using the Gene Set Enrichment Analysis (GSEA) and DAVID approaches (2-4). 
These tools evaluate the overlap of a specific gen set with gen sets from the MSigDB 
collections. The statistical significance of the overrepresentation of functional annotation 
terms is calculated on the basis of a hypergeometric testing. Two MSigDB collections 
(Biocarta and Reactome) were used. A False Discovery Rate (FDR) correction was applied 
for the results from GSEA-based results, and Bonferroni correction was applied for 
DAVID-based results.  
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